Worldwide Analog-to-Digital Converters Industry to 2027 - Featuring Asahi Kasei, Cirrus Logic and Microchip Technology Among Others
June 23, 2022 07:28 ET
|
Research and Markets
Dublin, June 23, 2022 (GLOBE NEWSWIRE) -- The "Analog-to-Digital Converters Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
MacroGenics to Participate in Upcoming Investor Conference
June 08, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Appointment of William Heiden to Board of Directors
May 23, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics to Participate in Upcoming Investor Conference
May 17, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
May 03, 2022 16:01 ET
|
MacroGenics, Inc.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
April 25, 2022 16:12 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
March 03, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Executive Promotion
February 28, 2022 07:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
February 24, 2022 16:01 ET
|
MacroGenics, Inc.
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeksPrioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and...
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
February 14, 2022 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...